TDZD-8

TDZD-8 is an inhibitor of GSK-3β, with an IC50 of 2 μM; TDZD-8 shows less potent activities against Cdk-1/cyclin B, CK-II, PKA, and PKC, with all IC50s of >100 μM.

Product Specifications

CAS Number

[327036-89-5]

Product Name Alternative

GSK-3β Inhibitor I; NP 01139

UNSPSC

12352005

Hazard Statement

H334

Target

GSK-3

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/TDZD-8.html

Purity

99.76

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(N1CC2=CC=CC=C2)N(C)SC1=O

Molecular Formula

C10H10N2O2S

Molecular Weight

222.26

Precautions

H334

References & Citations

[1]Martinez A, et al. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem. 2002 Mar 14;45 (6) :1292-9.|[2]Xie CL, et al. Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats. Sci Rep. 2016 Mar 21;6:23527.|[3]Sun A, et al. GSK-3β controls autophagy by modulating LKB1-AMPK pathway in prostate cancer cells. Prostate. 2016 Feb;76 (2) :172-83.